2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Expert faculty review and share their insights and perspectives on key findings in lung cancer presented at the 2022 ASCO Annual Meeting.
Stephen Liu, MD
Zofia Piotrowska, MD, MHS

Lung Cancer

Slidesets CHRYSALIS: Updated Phase I Trial Results of Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations
Slidesets NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC
Slidesets ATLANTIS: Analysis of Outcomes With Single-Agent Lurbinectedin After Lurbinectedin + Doxorubicin in Relapsed SCLC
Slidesets KRYSTAL-1 Trial of Adagrasib in Patients With Previously Treated Advanced KRASG12C-Mutated NSCLC: Analysis of Registrational Phase II Cohort
Slidesets Phase II TACTI-002 Trial: Updated Results With Eftilagimod Alpha Plus Pembrolizumab as First-line Therapy in Advanced NSCLC
Slidesets CHRYSALIS-2: Update of Amivantamab + Lazertinib in EGFR-Mutant NSCLC After Progression on Osimertinib and Chemotherapy
Slidesets Updated Results of a Phase I/IIa Trial of CLN-081, a Selective EGFR TKI, in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations
Slidesets Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases
Slidesets Phase I Trial of Patritumab Deruxtecan for Previously Treated Advanced NSCLC Without EGFR Activating Mutations
Slidesets OPAL: Phase II Trial of First-line Osimertinib Plus Platinum-Based Doublet Chemotherapy in EGFR-Mutated Advanced NSCLC
Slidesets SKYSCRAPER-02: Phase III Trial of First-line Atezolizumab + Carboplatin/Etoposide ± Tiragolumab, an Anti-TIGIT Antibody, in ES-SCLC
Slidesets CheckMate 816: Association of Pathologic Regression With EFS for Neoadjuvant Nivolumab + CT in Resectable NSCLC
Slidesets KRYSTAL-1: Phase Ib Report of Adagrasib Activity in Patients With KRAS G12C–Mutated NSCLC and Active, Untreated CNS Metastases

Expert faculty review and share their insights and perspectives on key studies in the management of lung cancer presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Stephen Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: September 1, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings